Mettler Toledo International Inc/: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 4, 2018 and accepted by EDGAR at May 4, 2018, 09:42 ET.
Management's discussion and analysis
As filed, 27,416 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.
General
Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the full year ending December 31, 2018.
Changes in local currencies exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.
We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.
Results of Operations – Consolidated
The following tables set forth items from our interim consolidated statements of operations and comprehensive income for the three month periods ended March 31, 2018 and 2017 (amounts in thousands).
| Three months ended March 31, 2018 (unaudited)% | 2017 (unaudited)% | |||
|---|---|---|---|---|
| Net sales | $660,821 | 100.0 | $594,567 | 100.0 |
| Cost of sales | 285,888 | 43.3 | 251,178 | 42.2 |
| Gross profit | 374,933 | 56.7 | 343,389 | 57.8 |
| Research and development | 34,713 | 5.3 | 31,200 | 5.3 |
| Selling, general and administrative | 200,674 | 30.4 | 185,656 | 31.2 |
| Amortization | 11,735 | 1.8 | 10,045 | 1.7 |
| Interest expense | 8,359 | 1.2 | 7,741 | 1.3 |
| Restructuring charges | 4,413 | 0.6 | 1,432 | 0.2 |
| Other charges (income), net | (2,400) | (0.4) | (6,533) | (1.0) |
| Earnings before taxes | 117,439 | 17.8 | 113,848 | 19.1 |
| Provision for taxes | 24,135 | 3.7 | 21,382 | 3.5 |
| Net earnings | $93,304 | 14.1 | $92,466 | 15.6 |
Net sales
Net sales were $660.8 million for the three months ended March 31, 2018, compared to $594.6 million for the corresponding period in 2017. This represents an increase in U.S. dollars of 11%. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 5% for the three months ended March 31, 2018. The Biotix acquisition contributed approximately 1.5% to local currency net sales for the three months ended March 31, 2018. These results compare to 12% local currency growth in the previous quarter of which the Troemner acquisition contributed approximately 1%. Global market conditions were generally favorable during the first quarter of 2018 and we continue to benefit from the execution of our global sales and marketing programs and development of our robust product portfolio. However, we remain cautious given the economic uncertainty that remains in certain regions of the world and market conditions are subject to change. We will also continue to face difficult prior period comparisons during 2018.
Net sales by geographic destination for the three months ended March 31, 2018 in U.S. dollars increased 6% in the Americas, 12% in Europe and 20% in Asia/Rest of World. In local currencies, our net sales by geographic destination increased 5% in the Americas and 10% in Asia/Rest of World and decreased 1% in Europe. The Biotix acquisition contributed approximately 2.5% to our local currency net sales growth in the Americas. A discussion of sales by operating segment is included below.
As described in Note 17 to our consolidated financial statements for the year ended December 31, 2017, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.
Net sales of products increased 12% in U.S. dollars and 5% in local currency for the three months ended March 31, 2018 compared to the prior period. The Biotix acquisition contributed approximately 2% to our net sales of products for the three months ended March 31, 2018. Service revenue (including spare parts) increased 9% in U.S. dollars and 3% in local currency during the three months ended March 31, 2018 compared to the corresponding period in 2017.
Net sales of our laboratory-related products and services, which represented approximately 52% of our total net sales for the three months ended March 31, 2018, increased 17% in U.S. dollars and 10% in local currencies during the three months ended March 31, 2018. The local currency increase in net sales of our laboratory-related products includes solid growth in most product categories. The Biotix acquisition also contributed approximately 3% to our net sales growth of laboratory-related products and services.
Net sales of our industrial-related products and services, which represented approximately 40% of our total net sales for the three months ended March 31, 2018, increased 5% in U.S. dollars and decreased 1% in local currencies during the three months ended March 31, 2018. The local currency decrease in net sales of our industrial-related products is related to a decline in product inspection and transportation and logistics, which both had strong growth in the prior year period, offset in part by growth in core-industrial, which included strong growth in China.
Net sales in our food retailing products and services, which represented approximately 8% of our total net sales for the three months ended March 31, 2018, increased 7% in U.S. dollars and was flat in local currencies during the three months ended March 31, 2018. Food retailing included strong project activity in the Americas, offset by reduced net sales in Europe due to difficult prior period comparisons.
Gross profit
Gross profit as a percentage of net sales was 56.7% for the three months ended March 31, 2018 compared to 57.8% for the corresponding period in 2017.
Gross profit as a percentage of net sales for products was 60.4% and 61.7% for the three month periods ended March 31, 2018 and 2017.
Gross profit as a percentage of net sales for services (including spare parts) was 44.4% for the three months ended March 31, 2018 compared to 44.7% for the corresponding period in 2017.
The decrease in gross profit as a percentage of net sales for the three months ended March 31, 2018 was primarily due to by the impact of foreign currency translation, unfavorable business mix and initial costs associated with new manufacturing facilities, offset in part by favorable price realization.
Research and development and selling, general and administrative expenses
Research and development expenses as a percentage of net sales was 5.3% for both the three months ended March 31, 2018 and 2017, respectively. Research and development expenses increased 12% in U.S. dollars and 5% in local currencies, during the three months ended March 31, 2018 compared to the corresponding period in 2017 relating to increased research and development project activity.
Selling, general and administrative expenses as a percentage of net sales were 30.4% for the three months ended March 31, 2018 compared to 31.2% in the corresponding period during 2017. Selling, general and administrative expenses increased 8% in U.S. dollars and 2% in local currencies, during the three months ended March 31, 2018 compared to the corresponding period in 2017. The local currency increase includes investments in our field sales organization and growth initiatives, offset in part by lower cash incentive expense compared with the expense relating to our strong previous year results and benefits from our cost savings initiatives.
Amortization, interest expense, other charges (income), net and taxes
Amortization expense was $11.7 million for the three months ended March 31, 2018 and $10.0 million for the corresponding period in 2017.
Interest expense was $8.4 million for the three months ended March 31, 2018 and $7.7 million for the corresponding period in 2017.
Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and related hedging activities, interest income and other items. Non-service pension benefits for the three months ended March 31, 2018 and 2017 were $1.6 million and $0.8 million, respectively. Other charges (income), net for the three months ended March 31, 2017 also includes a one-time gain of $3.4 million relating to the sale of a facility in Switzerland in connection with the our initiative to consolidate certain Swiss operations into a new facility.
The provision for taxes is based upon using our projected annual effective tax rate of 22% before non-recurring discrete items for the three month periods ended March 31, 2018 and 2017. The difference between our projected annual effective tax rate of 22% and the Company's reported tax rate of 21% and 19% during the three months ending March 31, 2018 and 2017, respectively, is related to the timing of excess tax benefits associated with stock option exercises.
On December 22, 2017, the Tax Cuts and Jobs Act (the "Act") significantly revised U.S. corporate income tax law. The Act includes, among other things, a reduction in the U.S. federal corporate income tax rate from 35% to 21% effective for taxable years beginning after December 31, 2017, and the implementation of a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings of foreign subsidiaries ("Transition Tax") that is payable over a period of up to eight years.
Our accounting for the Act is based upon reasonable estimates, however, our estimates may change upon the finalization of the Act's implementation and additional interpretive guidance from regulatory authorities. Among other things, we need to complete our analysis of historical foreign earnings and related taxes paid and our analysis of foreign cash equivalents. In addition, we need to complete our analysis of deemed repatriation of deferred foreign income and related state tax effects. We will complete our accounting for the above tax effects of the Act during 2018 as provided in SAB 118 and will reflect any adjustments to our provisional amounts as an adjustment to the provision for taxes in the reporting period in which the amounts are finally determined.
Results of Operations – by Operating Segment
The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 17 to our consolidated financial statements for the year ended December 31, 2017.
U.S. Operations (amounts in thousands)
| Three months ended March 31, | ||
|---|---|---|
| 2018 | 2017% | |
| Total net sales | $253,411 | $237,765 7% |
| Net sales to external customers | $229,745 | $215,353 7% |
| Segment profit | $34,245 | $38,822 (12)% |
Total net sales and net sales to external customers both increased 7% for the three months ended March 31, 2018 compared with the corresponding period in 2017. Net sales to external customers in our U.S. Operations benefited approximately 4% from the Biotix acquisition for the three months ended March 31, 2018. The increase in total net sales and net sales to external customers also includes solid results in our laboratory products against a difficult prior year comparison. We also experienced strong growth in retail due to the timing of project activity, offset in part by a decrease in product inspection related to particularly strong growth in the prior year period.
Segment profit decreased $4.6 million for the three months ended March 31, 2018 compared to the corresponding period in 2017 primarily due to initial costs associated with a new manufacturing facility and continued investments in our field sales and service organization offset in part by benefits from our margin expansion initiatives.
Swiss Operations (amounts in thousands)
| Three months ended March 31, 2018 | 2017 | %1) | |
|---|---|---|---|
| Total net sales | $176,048 | $157,300 | 12% |
| Net sales to external customers | $32,466 | $29,747 | 9% |
| Segment profit | $45,975 | $36,018 | 28% |
1) Represents U.S. dollar (decline) growth for net sales and segment profit.
Total net sales increased 12% in U.S. dollars and 6% in local currency for the three months ended March 31, 2018 compared to the corresponding period in 2017. Net sales to external customers increased 9% in U.S. dollars and 5% in local currency during the three months ended March 31, 2018 compared to the corresponding period in 2017. The increase in local currency net sales to external customers for the three month period ended March 31, 2018 includes solid growth in most product categories.
Segment profit increased $10.0 million for the three month period ended March 31, 2018 compared to the corresponding period in 2017. Segment profit during the three months ended March 31, 2018 includes the benefit of increased net sales volume, our margin expansion initiatives, lower cash incentive expense and favorable foreign currency translation, offset in part by increases in research and development.
Western European Operations (amounts in thousands)
| Three months ended March 31, 2018 | 2017 | %1) | |
|---|---|---|---|
| Total net sales | $206,384 | $190,265 | 8% |
| Net sales to external customers | $165,372 | $147,323 | 12% |
| Segment profit | $18,282 | $24,718 | (26)% |
1) Represents U.S. dollar (decline) growth for net sales and segment profit.
Total net sales increased 8% in U.S. dollars and decreased 5% in local currencies during the three month period ended March 31, 2018 compared to the corresponding period in 2017. Net sales to external customers increased 12% in U.S. dollars and decreased 2% in local currencies during the three month period ended March 31, 2018 compared to the corresponding period in 2017. The local currency decrease in net sales to external customers for the three months ended March 31, 2018 includes a significant decline in food retailing due to very strong project activity in the prior year period. The decline in local currency net sales also includes reduced inter-segment sales volume related to product transfers, as well as strong inter-segment product inspection sales in the previous year period.
Segment profit decreased $6.4 million for the three month period ended March 31, 2018 compared to the corresponding period in 2017. The decrease in segment profit includes a decline in local currency net sales volume (including inter-segment transfers), roll-in costs associated with our Blue Ocean program, increases in research and development, and investments in our sales and service organization, offset in part by benefits from our margin expansion initiatives, lower cash incentive expense and favorable foreign currency translation.
Chinese Operations (amounts in thousands)
| Three months ended March 31, 2018 | 2017 | %1) | |
|---|---|---|---|
| Total net sales | $174,337 | $143,713 | 21% |
| Net sales to external customers | $113,930 | $90,781 | 25% |
| Segment profit | $59,553 | $44,659 | 33% |
1) Represents U.S. dollar (decline) growth for net sales and segment profit.
Total net sales increased 21% in U.S. dollars and 12% in local currency for the three months ended March 31, 2018 compared to the corresponding period in 2017. Net sales to external customers increased 25% in U.S. dollars and 17% in local currency during the three months ended March 31, 2018 compared to the corresponding period in 2017. The increase in local currency net sales to external customers during the three months ended March 31, 2018 reflects strong growth in most product categories, especially laboratory products. While Chinese market conditions are currently favorable we will face difficult prior period comparisons during the remainder of 2018 due to our strong performance in 2017. In addition to the tough comparisons the Chinese economy has historically been volatile and market conditions may deteriorate, especially in industrial markets.
Segment profit increased $14.9 million for the three month period ended March 31, 2018 compared to the corresponding period in 2017. The increase in segment profit for the three month period ended March 31, 2018 includes increased local currency net sales volume, benefits from our margin expansion and cost savings initiatives, and favorable foreign currency translation.
Other (amounts in thousands)
| Three months ended March 31, 2018 | 2017 | %1) | |
|---|---|---|---|
| Total net sales | $120,948 | $112,960 | 7% |
| Net sales to external customers | $119,308 | $111,363 | 7% |
| Segment profit | $13,881 | $13,108 | 6% |
1) Represents U.S. dollar (decline) growth for net sales and segment profit.
Total net sales and net sales to external customers increased 7% in U.S. dollars and were flat in local currencies during the three month period ended March 31, 2018 compared to the corresponding period in 2017. Local currency growth in laboratory products was offset by declines in food retailing and product inspection related to strong project activity in the prior year period.
Segment profit increased $0.8 million for the three months ended March 31, 2018 compared to the corresponding period in 2017. The increase in segment profit is primarily due to benefits from our margin expansion initiatives and favorable foreign currency translation, offset in part by increased sales and service investments.
Liquidity and Capital Resources
Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.
Cash provided by operating activities totaled $76.6 million during the three months ended March 31, 2018, compared to $67.6 million in the corresponding period in 2017. The increase in 2018 includes a lower working capital outflow of $7.5 million.
Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $29.8 million for the three months ended March 31, 2018 compared to $21.0 million in the corresponding period in 2017. The increase is primarily related to investments in manufacturing facilities. We expect to make net investments in new or expanded manufacturing facilities of $30 million to $40 million over the next two years.
In 2017, we recorded a provisional one-time charge of $72 million for the estimated income tax effect of the Transition Tax associated with the Tax Cuts and Jobs Act of which $59 million is expected to be paid over a period of up to eight years. We plan to repatriate earnings from China, Switzerland, Germany, the United Kingdom and certain other countries in future years and expect the only additional cost associated with the repatriation of such earnings outside the United States will be any applicable withholding taxes. All other undistributed earnings are considered to be permanently reinvested. As of March 31, 2018, we have an immaterial amount of cash and cash equivalents outside the United States where undistributed earnings are considered permanently reinvested. Accordingly, we believe the tax impact associated with repatriating our undistributed foreign earnings will not have a material effect on our liquidity.
Senior Notes and Credit Facility Agreement
Our debt consisted of the following at March 31, 2018:
| March 31, 2018 U.S. Dollar | Other Principal Trading Currencies | Total | |
|---|---|---|---|
| $50 million Senior Notes, interest 3.67%, due December 17, 2022 | $50,000 | $— | $50,000 |
| $50 million Senior Notes, interest 4.10%, due September 19, 2023 | 50,000 | — | 50,000 |
| $125 million Senior Notes, interest 3.84%, due September 19, 2024 | 125,000 | — | 125,000 |
| $125 million Senior Notes, interest 4.24%, due June 25, 2025 | 125,000 | — | 125,000 |
| Euro 125 million Senior Notes, interest 1.47%, due June 17, 2030 | — | 155,260 | 155,260 |
| Debt issuance costs, net | (1,038) | (349) | (1,387) |
| Total Senior Notes | 348,962 | 154,911 | 503,873 |
| $800 million Credit Agreement, interest at LIBOR plus 87.5 basis points | 400,234 | 74,608 | 474,842 |
| Other local arrangements | 16 | 14,867 | 14,883 |
| Total debt | 749,212 | 244,386 | 993,598 |
| Less: current portion | (16) | (14,867) | (14,883) |
| Total long-term debt | $749,196 | $229,519 | $978,715 |
As of March 31, 2018, approximately $319.7 million was available under our Credit Agreement. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates.
We currently believe that cash flow from operating activities, together with liquidity available under our credit facility and local working capital facilities, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for at least the foreseeable future.
We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness.
In April 2018, two of our non-U.S. pension plans issued a loan of $39.6 million (Swiss franc 38 million) to a wholly owned subsidiary of the Company. The loan has an interest rate of LIBOR plus 87.5 basis points and a maturity date of April 2019 and a one year renewal term and, as such, will be classified as short-term debt on our consolidated balance sheet. The proceeds were used to pay down amounts outstanding on the existing credit facility.
Share Repurchase Program
The Company has a share repurchase program of which there was $464.7 million of common shares remaining to be repurchased under the program as of March 31, 2018. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of repurchases will depend on business and market conditions, stock price, trading restrictions, the level of acquisition activity, and other factors.
We have purchased 26.9 million shares since the inception of the program through March 31, 2018. During both the three months ended March 31, 2018 and 2017, we spent $118.8 million and $125.0 million on the repurchase of 187,880 shares and 275,088 shares at an average price per share of $632.03 and $454.37, respectively. We reissued 39,362 shares and 76,849 shares held in treasury for the exercise of stock options and restricted stock units during the three months ended March 31, 2018 and 2017, respectively.
Effect of Currency on Results of Operations
Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings go down. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also go down. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.
We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese Renminbi. The impact on our earnings before tax of the Chinese Renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.0 million to $1.3 million annually.
In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on our outstanding debt at March 31, 2018, we estimate that a 10% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $27.2 million in the reported U.S. dollar value of our debt.
Forward-Looking Statements Disclaimer
You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue”.
We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position , capital expenditures, cash flow, tax-related matters, compliance with laws, and effects of acquisitions.
Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2017 Annual Report on Form 10-K.
Market risk
As filed, 174 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of March 31, 2018, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Controls and procedures
As filed, 702 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 201 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For the three months ended March 31, 2018 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-01-01 to 2018-03-31 | $660.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2018-01-01 to 2018-03-31 | $202.6m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2018-01-01 to 2018-03-31 | $374.9m | us-gaap:GrossProfit |
| Research and development | 3 months2018-01-01 to 2018-03-31 | $34.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-01-01 to 2018-03-31 | $200.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $8.4m | us-gaap:InterestExpense |
| Income tax | 3 months2018-01-01 to 2018-03-31 | $24.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-01-01 to 2018-03-31 | $93.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | $3.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-01-01 to 2018-03-31 | $3.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-01-01 to 2018-03-31 | 26,095,647 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | $76.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $29.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2018-01-01 to 2018-03-31 | $118.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2018-03-31 | $98.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $927.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $2.51bn | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $636.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $1.95bn | us-gaap:Liabilities |
| Long-term debt | At period end2018-03-31 | $978.7m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2018-03-31 | $560.7m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2018-03-31 | 25,392,875 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001037646-18-000011. Last ingested by Listed: Nov 13, 2026, 02:43 ET. Listed shows no prices and gives no investment advice.